Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise and Tocilizumab for Visceral Adipose Tissue
NCT02901496Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2016
- Primary completion
- Apr 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab in abdominal obesity (5 arms), sponsored by Rigshospitalet. Primary endpoint: Changes in visceral fat mass at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
abdominal obesity
Beyond the preview
Go deeper on NCT02901496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901496.